All News
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha (PEG-IFNα) in patients with chronic hepatitis B (CHB) compared with PEG-IFNα only treatment.
First Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge’s team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD
Recently, NyokAssist™ was first-in-man (FIM) use, supporting High-risk PCI completed by Dr. Junbo Ge's team from Zhongshan Hospital in Shanghai.
Baird Medical’s Single-Use Sterile Biopsy Needle Receives Approval from Jiangsu Medical Products Administration in China
Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced that its subsidiary, Nanjing Changcheng Medical Equipment Co., Ltd., has received approval of its Single-Use Sterile Biopsy Needle ("SSBN") from Jiangsu Medical Products Administration, the drug regulatory body for Jiangsu Province in China.
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and commercialization of biologics in immuno-oncology, today announced that its fully human anti-PD-1 monoclonal antibody, Zimberelimab injection (YuTuo®, GLS-010) has received marketing approval from the China National Medical Products Administration (NMPA)
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs).
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase
树兰医疗递表港交所：华东最大的社会办医疗机构，另已合作14家医疗机构
“据IPO早知道消息，树兰医疗管理股份有限公司（以下简称“树兰医疗”）于2023年8月28日正式向港交所递交招股说明书，中金公司和中信证券担任联席保荐人。成立于2013年的树兰医疗作为一家集健康医疗服务、医学科研、医学教育为一体的中国科技型社会办医疗集团，截至2023年3月31日拥有并运营三家社会办综合医疗机构，并已向中国14家合作医院提供医院管理服务。同时，树兰医疗还提供数字医疗平台服务、医疗检验服务、临床试验服务、供应链服务等多项平台服务。具体来看树兰医疗的三大业务板块：其一、健康医疗服务。截至目前，树兰医疗拥有树兰(杭州)医院、树兰(安吉)医院以及树兰(衢州)医院三家社会办医综合医疗机构——其中，树兰(杭州)医院是树兰医疗于2015年12月开始运营的首家医院，其是少数获评三級甲等医院的社会办医疗机构，并于2017年成为通过JCI认证的国际医院。截至2023年3月31日，树兰(杭州)医院已开设1,000张床位，并设有46个临床专科和13个医技科室。” Continue reading at the original source, linked here.
IVI and the Madagascar Institute for Vaccine Research launch typhoid conjugate vaccine campaign for infants and children
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Madagascar Institute for Vaccine Research (MIVR) at the University of Antanararivo held a ceremony today to launch a mass vaccination campaign against typhoid in the Arivonimamo and Antananarivo-Atsimondrano districts of Madagascar.
GC Biopharma to organize “Donate Blood with Love”, a healthy way of giving back to the community
All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value.
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics
GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin, South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine.
